disclosure. Additionally, no participants cited regret about receiving their results. **Conclusions:** While disclosure of biomarker positivity may result in mild increases in acute anxiety or distress, or fewer positive emotions, it does not result in clinically significant emotional reactions and was not associated with regret. Overall, findings are consistent with literature indicating safety of biomarker disclosure procedures for symptomatic individuals. Future research should follow participants over longer periods to evaluate the impacts of biomarker disclosure.

Categories: Dementia (Alzheimer's Disease) Keyword 1: dementia - Alzheimer's disease Keyword 2: mild cognitive impairment Keyword 3: positron emission tomography Correspondence: Mary Lesniak Research Program on Cognition & Neuromodulation Based Interventions, Department of Psychiatry – Neuropsychology Section, University of Michigan Medical School, Ann Arbor, MI Marles@umich.edu

41 Examining the independent and additive effects of family history of dementia and apolipoprotein e4 on neurocognitive performance among people with HIV

Maulika Kohli¹, Laura M Campbell¹, Erin Sundermann², Mark W Bondi², Paul Gilbert³, Donald Franklin², Scott Letendre², Robert K Heaton², Payal Patel⁴, Susan Morgello⁵, Benjamin Gelman⁶, David Clifford⁷, Raeanne C Moore². David J Moore² ¹SDSD/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA. ²UC San Diego, San Diego, CA, USA. ³San Diego State University, San Diego, CA, USA. ⁴University of Washington, Seattle, WA, USA. ⁵The Icahn School of Medicine at Mount Sinai, New York City, NY, USA. ⁶University of Texas Medical Branch at Galveston, Gaveston, TX, USA. ⁷Washington University in St. Louis, St. Louis, MO, USA

Objective: Among people with HIV (PWH), the apolipoprotein e4 (APOE-e4) allele, a genetic marker associated with Alzheimer's disease

(AD), and self-reported family history of dementia (FHD), considered a proxy for higher AD genetic risk, are independently associated with worse neurocognition. However, research has not addressed the potential additive effect of FHD and APOE-e4 on global and domainspecific neurocognition among PWH. Thus, the aim of the current investigation is to examine the associations between FHD, APOE-e4, and neurocognition among PWH.

Participants and Methods: 283 PWH (Mage=50.9; SDage=5.6) from the CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) study completed comprehensive neuropsychological and neuromedical evaluations and underwent APOE genotyping. APOE status was dichotomized into APOE-e4+ and APOE-e4-. APOE-e4+ status included heterozygous and homozygous carriers. Participants completed a free-response question capturing FHD of a first- or second-degree relative (i.e., biologic parent, sibling, children, grandparent, grandchild, uncle, aunt, nephew, niece, half-sibling). A dichotomized (yes/no), FHD variable was used in analyses. Neurocognition was measured using global and domain-specific demographically corrected (i.e., age, education, sex, race/ethnicity) T-scores. ttests were used to compare global and domainspecific demographically-corrected T-scores by FHD status and APOE-e4 status. A 2x2 factorial analysis of variance (ANOVA) was used to model the interactive effects of FHD and APOEe4 status. Tukey's HSD test was used to followup on significant ANOVAs.

Results: Results revealed significant differences by FHD status in executive functioning (t(281))=-2.3, p=0.03) and motor skills (t(278)=-2.0, p=0.03) such that FHD+ performed worse compared to FHD-. Differences in global neurocognition by FHD status approached significance (t(281)=-1.8, p=.069). Global and domain-specific neurocognitive performance were comparable among APOE-e4 carriers and noncarriers (ps>0.05). Results evaluating the interactive effects of FHD and APOE-e4 showed significant differences in motor skills (F(3)=2.7. p=0.04) between the FHD-/APOE-e4+ and FHD+/APOE-e4- groups such that the FHD+/APOE-e4- performed worse than the FHD-/APOE-e4+ group (p=0.02).

Conclusions: PWH with FHD exhibited worse neurocognitive performance within the domains of executive functioning and motor skills, however, there were no significant differences in neurocognition between APOE-e4 carriers and noncarriers. Furthermore, global neurocognitive performance was comparable across FHD/APOE-e4 groups. Differences between the FHD-/APOE-e4+ and FHD+/APOE-e4- groups in motor skills were likely driven by FHD status. considering there were no independent effects of APOE-e4 status. This suggests that FHD may be a predispositional risk factor for poor neurocognitive performance among PWH. Considering FHD is easily captured through selfreport, compared to blood based APOE-e4 status, PWH with FHD should be more closely monitored. Future research is warranted to address the potential additive effect of FHD and APOE-e4 on rates of global and domain-specific neurocognitive decline and impairment over time among in an older cohort of PWH, where APOEe4 status may have stronger effects.

Categories: Dementia (Alzheimer's Disease) Keyword 1: HIV/AIDS Keyword 2: neurocognition Keyword 3: dementia - Alzheimer's disease Correspondence: Maulika Kohli, SDSD/UC San Diego Joint Doctoral Program in Clinical Psychology, mkohli@health.ucsd.edu

42 Cognitive and Neuroanatomic Correlates of Olfactory Function in Cognitively Unimpaired and Impaired Older Adults

Michael DiCalogero¹, Vidyulata Kamath², David Wolk¹, Sandhitsu Das¹, Long Xie³, Jacqueline Lane¹, Kimberly Halberstadter¹, <u>Dawn</u> <u>Mechanic-Hamilton¹</u>

¹University of Pennsylvania, Perelman School of Medicine, Department of Neurology, Philadelphia, Pennsylvania, USA. ²Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, Baltimore, Maryland, USA. ³University of Pennsylvania, Perelman School of Medicine, Department of Radiology, Philadelphia, Pennsylvania, USA

Objective: Olfactory function declines during normal aging; however, accelerated olfactory decline is observed in neurodegenerative diseases, such as Alzheimer's disease (AD). Moreover, olfactory deficits in pre-clinical AD are associated with future cognitive decline. Odor identification and memory deficits have been consistently reported in early stage AD indicating its potential sensitivity to AD pathophysiology in olfactory and limbic structures, yet few studies of olfaction have incorporated structural measures in a wellcharacterized cohort of older adults. In the current study we examined the association between odor identification impairment, cognition, and medial temporal lobe (MTL) subregions in cognitively unimpaired and impaired older adults.

Participants and Methods: We enrolled 140 participants (age=72.25±6.54, 56% female. years of education=16.30±2.63, 82% Caucasian, 15% Black/AA, 3% Multiracial) from the Penn Alzheimer's Disease Research Center Clinical Cohort. Participants completed the Sniffin' Sticks Odor Identification Test (SS-OIT), cognitive testing (NACC UDS2 or UDS3 and additional cognitive tests), and MRI scans (3T Siemens MAGNETOM Prisma MRI scanner). For the SS-OIT, participants were presented with 16 odorants using felt-tipped pen dispensers and asked to identify each odor from four multiplechoice options. Scores range from 0 to 16. Additionally, cognitive domains were created by averaging z-scores from tests within each domain: attention, memory, language, executive function, and visuospatial. This cohort was divided into participants with unimpaired cognition (n=96) and impaired cognition (MCI, dementia; n=44) using established normative data and consensus diagnosis. Linear regressions were performed to examine the association between SS-OIT score, each cognitive domain, and MTL measurements for unimpaired and impaired groups. For all analyses, we controlled for age, race, sex, education, smoking status, and hypertension and additionally for MOCA score and intracranial volume with MTL measurements. Results: In the unimpaired group, SS-OIT significantly associated with language (p<.05). In the impaired group, SS-OIT significantly associated with language and memory (p<.05). In the unimpaired group, SS-OIT significantly associated with right anterior hippocampal volume (p<.05). In the impaired group, significant associations were found between SS-OIT and right anterior hippocampal volume (p<.05) and left hippocampal mean thickness (p<.05). Additionally, SS-OIT significantly associated with left and right entorhinal cortex volume (p<.05) and mean thickness (p<.05).